article thumbnail

“Game-changing” personalised cancer vaccine enters UK clinical trials   

Drug Discovery World

A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. The vaccines are personalised to each patient after a tumour sample is removed during surgery and then analysed using DNA sequencing. in the combination arm and 62.2%

article thumbnail

Cancer vaccine shows sustained improvement in survival rates

Drug Discovery World

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.”

Vaccine 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

US approves first mRNA vaccine since Covid-19

Drug Discovery World

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. This approval is also the first time an mRNA vaccine has been approved for a disease other than Covid-19.”

Vaccine 147
article thumbnail

First UK patients receive experimental mRNA therapy for cancer

Drug Discovery World

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The study will assess the therapy administered alone or in combination with immune checkpoint inhibitor pembrolizumab.

Therapies 278
article thumbnail

Cancer vaccine developer secures £12.8m seed financing

Drug Discovery World

Jonathan Kwok, CEO and Co-founder of Infinitopes, said: “Our therapies are emerging at a time when blockbuster checkpoint inhibitors are hitting their peak, capable of preventing tumour recurrence in 30-40% of patients at best. Diana Spencer, Senior Digital Content Editor, DDW The post Cancer vaccine developer secures £12.8m

Vaccine 147
article thumbnail

Breakthrough Therapy designation for pneumococcal disease vaccine

Drug Discovery World

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. . The post Breakthrough Therapy designation for pneumococcal disease vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130
article thumbnail

IO Biotech announces data for therapeutic cancer vaccine

Drug Discovery World

Jonathan Riess, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, presented encouraging early clinical and biomarker data supporting the combination treatment for patients with metastatic non-small cell lung cancer (NSCLC). These data were presented at the IASLC 2023 World Conference on Lung Cancer (WCLC).

Vaccine 130